Generic diabetes combo drug shows promise in healthy volunteers
NCT ID NCT07372118
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a generic version of the diabetes medication Synjardy XR (empagliflozin and metformin) works the same as the brand-name drug. Thirty-two healthy adults took a single dose of either the generic or brand tablet under fasting conditions. The goal was to see if the generic releases the same amount of medicine into the bloodstream, which could lead to a more affordable option for people with type 2 diabetes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Empagliflozin and Metformin extended-release tablets
What this could lead to
If successful, this study could help bring a lower-cost generic version of Synjardy XR to market for type 2 diabetes patients.
What could go wrong
This is a small, early-phase bioequivalence study in healthy volunteers, not patients. Results may not predict real-world effectiveness or safety in people with diabetes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Veeda Clinical Research Limited
Ahmedabad, Gujarat, 384205, India